Propanc Biopharma (PPCB) Change in Receivables (2013 - 2025)
Propanc Biopharma (PPCB) posted quarterly Change in Receivables of $8572.0 for Q4 2025, up 954.64% year-over-year from $812.79 in Q4 2024, and up 181.7% quarter-over-quarter from $3043.0 in Q3 2025.
Propanc Biopharma (PPCB) Change in Receivables (2013 - 2025) Analysis & Trends
Propanc Biopharma (PPCB) has reported Change in Receivables for 13 consecutive years, with $8572.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Change in Receivables rose 954.64% year-over-year to $8572.0; the TTM figure through Dec 2025 stood at $14772.0 (up 990.95% YoY), while the FY2025 annual figure was $2405.0, up 3287.32% from the prior year.
- Change in Receivables advanced to $8572.0 in Q4 2025 per PPCB's latest filing, from $3043.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $8572.0 in Q4 2025 and bottomed at -$3537.0 in Q1 2022.
- Historically, Change in Receivables has averaged $775.1 across 5 years, with a median of $491.5 in 2022.
- Annual changes were most pronounced in 2024 — Change in Receivables tumbled 425.49% — and 2025, when it jumped 1112.35%.
- Propanc Biopharma's Change in Receivables stood at $3354.0 in 2021, then plunged by 48.87% to $1715.0 in 2022, then sank by 35.34% to $1109.0 in 2023, then tumbled by 190.44% to -$1003.0 in 2024, then soared by 954.64% to $8572.0 in 2025.
- Business Quant data shows PPCB's Change in Receivables at $8572.0 in Q4 2025, $3043.0 in Q3 2025, and $1525.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 31.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 37.16 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 94.29 Mn |
| 10 | Propanc Biopharma | 587,855.41 | 587,855.41 | - | 8,572.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 8,572.00 |
| Dec 31, 2025 | 8,572.00 |
| Sep 30, 2025 | 3,043.00 |
| Sep 30, 2025 | 3,043.00 |
| Jun 30, 2025 | 1,525.00 |
| Jun 30, 2025 | 1,525.00 |
| Mar 31, 2025 | 1,632.00 |
| Mar 31, 2025 | 1,632.00 |
| Dec 31, 2024 | -1,003.00 |
| Dec 31, 2024 | -1,003.00 |
| Sep 30, 2024 | 251.00 |
| Sep 30, 2024 | 251.00 |
| Jun 30, 2024 | -2,391.00 |
| Jun 30, 2024 | -2,391.00 |
| Mar 31, 2024 | 1,485.00 |
| Mar 31, 2024 | 1,485.00 |
| Dec 31, 2023 | 1,109.00 |
| Dec 31, 2023 | 1,109.00 |
| Sep 30, 2023 | -132.00 |
| Sep 30, 2023 | -132.00 |